ORKA · Oruka Therapeutics, Inc.

Current Thesis

The binary that defined the prior read has resolved positive. On 2026-04-27 the EVERLAST-A Phase 2a of ORKA-001 (anti-IL-23, twice-yearly maintenance target) posted 63.5% PASI 100, 83% PASI 90 and 84% IGA 0/1 at Week 16 complete-clearance numbers in bimekizumab territory delivered from an IL-23 dosed far less often than Skyrizi. The April analyst cluster ($125–$200 PTs) plus the data beat drove a run to a 52-week high of $91, and a ~$700.35M follow-on (announced 2026-05-06) priced straight into the strength rather than as a stealth dump closing out the pre-offering overhang thesis. The problem now is timing, not quality: the accelerating leg is spent. Shares faded to ~$55 by 2026-06-02 and sit at $60.14 (2026-06-05), bleeding on a June 2026 lock-up expiry layered on top of the freshly enlarged share count, with no data catalyst until H2 2026 and the two real binaries (EVERLAST-B Phase 2b, ORKA-002 Phase 2) not until 2027. This is a validated, cash-flush clinical name in a post-catalyst correction a watch-for-the-base situation, not a momentum entry at current price.

Bull Case

• Phase 2a beat, 2026-04-27: ORKA-001 hit 63.5% PASI 100, 83% PASI 90, 84% IGA 0/1 at Week 16 (EVERLAST-A). PASI 90 above Skyrizi's ~74% benchmark and PASI 100 in bimekizumab range best-in-class clearance from a molecule targeting Q6M-to-yearly dosing.
• Cash removes the usual biotech kill switch: the $700.35M follow-on (2026-05-06, alongside the Halozyme deal) lifts cash to ~$1.1B+ by mid-2026, funding operations through the 2027 Phase 2b and ORKA-002 Phase 2 readouts plus a year. Near-term raise risk is off the table.
• Sell-side re-rated hard on data: Guggenheim raised PT to $200 (from $125), Leerink to $120, HC Wainwright to $120, Piper Sandler Overweight reaffirmed Strong Buy consensus, cited averages $137–$142.
• Halozyme Hypercon license, 2026-05-06: hyperconcentration tech cuts injection volume, making subcutaneous delivery viable at the high ORKA-001 doses de-risks the patient-convenience pitch (mid-single-digit royalty to HALO + milestones).
• Second long-acting shot on goal: ORKA-002 (anti-IL-17A/F) Phase 1 (2026-01-12) showed a 75–80 day half-life, >3x bimekizumab, comparable Cmax twice-yearly psoriasis / quarterly HS dosing. Platform optionality beyond a single asset.
• Long-dated IBD optionality, 2026-05-29: Paragon amendment broadened the IL-23 license to all indications including inflammatory bowel disease, with change-of-control language that accelerates the timeline an M&A sweetener.

Bear Case

• Post-data unwind in progress: down ~34% from the $91 high (early May) to ~$55 (2026-06-02), a weak bounce to $60.14 (2026-06-05). The chart is correcting, not basing higher.
• June 2026 lock-up expiry: newly tradable shares add supply into a tape still digesting the $700M raise. This is the named driver of the slide per multiple desks flow, not fundamentals, runs the next several weeks.
• Catalyst vacuum: no data event until H2 2026 (EVERLAST-A 52-week durability subset). The decisive binaries EVERLAST-B Phase 2b (PASI 100 at W16) and ORKA-002 Phase 2 read out in 2027. Months with nothing to bid the tape.
• Rich on a years-away win: $3.63B market cap, zero revenue, $94.19M TTM net loss pricing a clean Phase 3 outcome still gated by a 2027 readout. PT dispersion $100–$200 signals the Street has no shared read.
• IBD is undosable for years: per the 2026-05-29 amendment, no IBD monotherapy trial until 2030-06-01 (combination 2028-06-01) absent a change of control optionality, not a development driver.
• Crowded indication: plaque psoriasis is well-served (Skyrizi, Tremfya, Bimzelx, Sotyktu, Taltz). The entire edge is dosing frequency, which Phase 2b must convert into durable once-yearly PASI 100 maintenance to justify the multiple.

Setup & Price Structure

• 2026-06-05 close $60.14 (−3.44%); market cap $3.63B; 60.31M shares out; 52-week range $10.77–$91.00.
• Topped at the $91 52-week high in early May post-data, faded to ~$55 on 2026-06-02 (≈−40% off high), reclaimed $60 by 2026-06-05. Currently chopping in the high-$50s to low-$60s.
• The high-$50s ($52–$55) is the post-raise / lock-up-fear shelf roughly the area where the $700M follow-on cleared. A weekly close below it means supply is winning.
• Constructive only if the low-$60s zone (the flattening 20-EMA region) is reclaimed and ~$66 (mid-May level) recovers on expanding volume that would mark a base rebuild rather than continued unwind.
• Classification: this is a post-catalyst correction with a supply overhang, not an accelerating, cluster-confirmed setup. The momentum leg (analyst cluster 2026-04-06→15 plus the 2026-04-27 beat) is in the rearview.

Catalyst Calendar (next 30 days)

• ~June 2026 (est., within window) lock-up expiration: dominant near-term event; newly tradable shares hit the float. Primary driver of the May→June slide. Exact date unverified confirm on IR/EDGAR; it is a supply event, not a buy catalyst.
• ORKA-002 Phase 2 psoriasis initiation guided 1H 2026: a start/first-patient-dosed press release is possible in June, but it is a milestone, not a data print.
• No data readout in the 30-day window. Next data: EVERLAST-A 52-week durability subset H2 2026; ORKA-002 Phase 2 HS start 2H 2026; EVERLAST-B Phase 2b + ORKA-002 Phase 2 data 2027.
• No earnings in window Q2 2026 print expected ~August 2026 (verify exact date before any entry inside a 3-day blackout).

What Would Change Our Mind

• Re-accelerate (entry trigger): lock-up clears, the high-$50s base holds, and price reclaims the low-$60s 20-EMA then breaks ~$66 on expanding volume or a fresh dated positive (ORKA-002 Phase 2 start with clean design, EVERLAST-A 52-week durability in H2 2026) re-arms the narrative.
• Kill it (skip/avoid): a weekly close below ~$52 confirms the Phase 2a pop is fully unwound and lock-up supply is overwhelming demand treat as a value trap until a new base forms; do not average into the slide.
• M&A re-rate (tail): a strategic bid (AbbVie, JNJ, UCB, Lilly) would re-rate the stock instantly given the change-of-control clause that accelerates the IBD field expansion optionality, not a base case.

Correlation Notes

• Reads through to the long-acting immuno-derm complex and psoriasis incumbents: ABBV (Skyrizi/Rinvoq), JNJ (Tremfya), UCB (Bimzelx), LLY (Taltz). A competitor durability or safety surprise reprices the dosing-frequency edge directly.
• High beta to the clinical-biotech risk cohort (XBI/IBB) and rate-sensitive as a long-duration, pre-revenue name a risk-off or rising-rate tape pressures the whole group irrespective of asset quality.
• HALO (Halozyme) is a partnership read-through; a Hypercon delivery setback would dent the convenience thesis.
• For the next ~30 days the idiosyncratic supply story (lock-up + enlarged float) dominates macro the stock trades on its own flow more than on the sector.